FAM210A: A Potential Drug Target Or Biomarker (G125228)

Target Name: FAM210A

NCBI ID: G125228

FAM210A

FAM210A: A Potential Drug Target Or Biomarker

FAM210A, also known as FAM210A variant 1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The FAM210A gene is located on chromosome 16 and encodes for a protein known as FAM210A, which is a key regulator of the immune response and has been implicated in a number of diseases. The FAM210A protein plays a role in the regulation of T cell development, differentiation, and function, and is also involved in the regulation of inflammation and cellular stress.

Studies have suggested that FAM210A may be a drug target or biomarker for a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, research has shown that high levels of FAM210A are associated with an increased risk of developing multiple sclerosis, a neurodegenerative disease that affects the central nervous system.

Additionally, FAM210A has been shown to be involved in the regulation of cancer cell growth and survival. For example, studies have shown that FAM210A is involved in the regulation of the activity of the oncogene PD-L1, which is a known regulator of cancer cell growth and survival.

FAM210A may also be a potential biomarker for autoimmune disorders, as it has been implicated in the regulation of immune cell function and the development of autoimmune diseases. For example, research has shown that FAM210A is involved in the regulation of the production of antibodies, which are a key component of the immune response.

In addition to its potential as a drug target or biomarker, FAM210A is also of interest as a potential therapeutic target for a number of diseases. For example, research has shown that inhibiting the activity of FAM210A has the potential to treat a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

FAM210A is also of interest as a potential target for cancer therapy, as research has shown that inhibiting the activity of FAM210A has the potential to inhibit the development and progression of a variety of cancer types. For example, studies have shown that inhibiting the activity of FAM210A has the potential to inhibit the growth of cancer cells and reduce their ability to evade the immune response.

Overall, FAM210A is a gene that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in the regulation of immune cell function and the development of disease.

Protein Name: Family With Sequence Similarity 210 Member A

Functions: May play a role in the structure and strength of both muscle and bone

The "FAM210A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM210A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets